咪苯嗪酮对花生四烯酸诱导的大鼠脑血栓形成的影响

花生四烯酸(AA)0.25～1 mg·kg~(-1)经颈内动脉注射能诱发大鼠同侧大脑半球脑内血栓形成,明显增加伊文思蓝通过血脑屏障渗入脑实质的量,峰值为205±s 50 mg·kg~1脑组织,相应对照组为10±s 5mg·kg~1,咪苯嗪酮0.25～0.5mg·kg~1 iv能对抗AA引起的大鼠脑血栓形成,显著降低脑实质内伊文思蓝的含量,作用呈剂量依赖性,且强于哒唑氧苯     

4，5－二氢－6－［（苯乙酰基－哌嗪基）苯基］－5－甲基－3（2H）－哒嗪酮对血小板聚集，花生四烯酸代谢及cAMP含量的影响

４，５－二氢－６－［（苯乙酰基－哌嗪基）苯基］－５－甲基－３（２Ｈ）－达嗪酮（ＳＭＤ。）０．１一２．５ｐｍｏｌ·Ｌ能使血小板激活因子（ＰＡｎ及血栓素Ａ，类似物Ｕ４６６１９诱导的兔血小板聚集剂量一效应曲线不移且最大反应降低。其ｐＤ２分别为６．０±ｓ０．４及６．１±ｓ０．３ＳＭⅡ４还能抑制ＡＤＬ花生四烯酸（ＡＡ）及Ｕ４６６１９诱导的人血小板聚集，其ＩＣ（５０）分别是１２，１３及１．６μｍｏｌ．Ｌ．用放射性薄层层折及放射免疫测定法分别检测血小板ＡＡ代谢产物及ｃＡＭＰ含量表明，ＳＭⅡ４对血小板ＡＡ代谢没有显著影响，但能剂量依赖性地升高血小板内ｃＡＭＰ含量，ＰＡＦμｍｏｌ·Ｌ不能改变此作用     

咪苯嗪酮对血小板聚集、血栓形成和血小板环磷酸腺苷含量的影响

本文观察了新型强心剂咪苯嗪酮(Cl-914)对血小板聚集、血栓形成和血小板cAMP含量的影响。用比浊法测定Cl-914体外抑制AA,ADP和胶原诱导兔血小板聚集的IC_(50),分别为2.6,8.9和15.8μM;大鼠iv Cl-914 1.25mg/kg能抑制实验性血栓形成,20 mg/kg能抑制上述三种诱导剂引起的血小板聚集。在体外,用竞争性蛋白结合法测定,CI-914可使洗涤兔血小板cAMP含量明显升高。CI-914能以剂量依赖方式协同PGE_1抑制血小板聚集和升高血小板cAMP的含量。提示CI-914升高血小板cAMP含量可能是其抑制血小板聚集和抗血栓形成的主要机理。     

咪苯嗪酮对花生四烯酸环氧酶途径代谢产物的选择性影响

兔iv咪苯嗪酮(CI—914)20 mg/kg,用RIA法测定其血浆中TXB_2和6—kcto—PGF_(1α)含量,给药后30 min和60 min.6—keto—PGF_(1α)/TXB_2比值显著升高(p<0.05).在用放射性TLC法进行的洗涤大鼠血小板~(14)C—AA代谢实验中,CI—914在2～500 μmol/L范围内以剂量依赖方式抑制大鼠血小板TXB_2生成,IC_(50)为51.5μmol/L,对HHT生成的抑制明显弱于对TXB_2生成的抑制作用;在相同剂量范围内,CI—914同时以剂量依赖方式使PGE_2,PGF_(2α)和PGD_2生成增加.在相同实验条件下,50μmol/L的已知的TXA_2合成酶抑制剂DAZ,与大剂量CI—914的实验结果类似.上述结果提示,CI—914对血小板TXA_2合成酶可能具有选择性抑制作用.     

Synthesis of 6-[(4-imidazol-1-yl)-phenyl]-4-phenyl 4,5-dihydro-2H-pyridazin-3-one: a potential blood platelet aggregation inhibitor

A new 4,5 diaryl pyridazin-3-one, an analogue of imazodan and Cl-930 was prepared starting from conveniently available chalcone. The resulting derivative was tested in order to determine the area of pharmacological activity. This compound was devoid of positive inotropic effects but showed an important inhibition of PAF-acether induced blood platelet aggregation in vitro with a Cl50 value of 3,4 microM. Ex vivo, anti-aggregating effect against PAF-acether was less important with a DE50 value of 63 mg/kg per os.     

6-[4-(取代哌嗪基)苯基]-4,5-二氢-3(2H)-哒嗪酮类化合物的三维定量构效关系研究

本文采用比较分子力场分析法(CoMFA),系统研究了自行合成的34个6-[4-(取代哌嗪基)苯基]-4,5-二氢-3(2H)-哒嗪酮类化合物和参比化合物CCI-17810的三维定量构效关系.所建立CoMFA模型的交叉相关系数q2值为0.663,具有较强的预测能力.利用CoMFA模型的三维等值线图直观地解释了化合物的构效关系,阐明了化合物结构中哌嗪末端N原子上不同取代基对抗血小板聚集活性的影响,为进一步结构优化提供了重要信息.     

4,5-二氢-3(2H)-哒嗪酮衍生物的合成及抑制血小板聚集作用

目的设计并合成6-(4-取代苯基)-4,5-二氢-3(2H)-哒嗪酮衍生物,并对其抗血小板聚集活性进行初步评价.方法以苯酚为原料,经多步反应合成目标化合物,并以Born比浊法测试目标化合物的抗血小板聚集活性.结果共合成16个新化合物,经MS、1H-NMR确证其结构.其中12个化合物具有一定的抗血小板聚集活性.结论中间连接链的长度影响此类化合物抑制血小板聚集活性.当n=3、4时,所有化合物均具有一定的活性;当n=2时,仅有两个化合物具有活性.     

6-[4-(4′-吡啶)氨基苯]-4,5-二氢-3(2H)哒嗪酮对大鼠胸主动脉环收缩功能的影响

目的研究新型钙增敏强心剂6-[4-(4′-吡啶)氨基苯]-4,5-二氢-3(2H)哒嗪酮(MCI-154)的扩血管作用机制。方法采用生物张力换能器及生理记录仪测定大鼠离体胸主动脉环和蜕膜胸主动脉环的收缩张力。结果MCI-154可浓度依赖性抑制1nmol.L-1~10μmol.L-1去甲肾上腺素(pD2′为4.21±0.23)和80mmol.L-1KCl(IC50为7μmol.L-1)引起的血管环收缩,提示其可通过抑制血管平滑肌细胞膜上受体操纵性和电压依赖性钙通道而减少胞外钙内流。在无Ca2+K-H液中,MCI-154预处理可浓度依赖性降低3μmol.L-1苯肾上腺素(IC50为5μmol.L-1)及20mmol.L-1咖啡因(IC50为16μmol.L-1)引起的血管环收缩张力,提示其可抑制血管平滑肌细胞胞内钙释放。在1μmol.L-1Ca2+溶液中,MCI-154可显著降低蜕膜血管环收缩张力(IC50为10μmol.L-1),提示其可降低血管平滑肌对Ca2+的敏感性。结论MCI-154可通过抑制血管平滑肌胞外钙内流、胞内钙释放和降低其对Ca2+敏感性来降低血管平滑肌收缩张力,体外具有扩血管效应。     

Cardiotonic agents. 2. Synthesis and structure-activity relationships of 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: a new class of positive inotropic agents

A series of 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds were synthesized and evaluated for positive inotropic activity. Most members of this series produced dose-related increases in myocardial contractility that were associated with relatively minor increases in heart rate and decreases in systemic arterial blood pressure. Introduction of a methyl substituent at the 5-position of 1 (CI-914) produced the most potent compound in this series (11, CI-930). Compound 1 is more potent than amrinone whereas compound 11 is more potent than milrinone. The inotropic effects of 1 and 11 are not mediated via stimulation of beta-adrenergic receptors. Selective inhibition of cardiac phosphodiesterase fraction III represents the principal component of the positive inotropic action of 1 and 11.     

6-(4-取代乙酰氨基苯基)-4,5-二氢-3(2H)-哒嗪酮类化合物的合成及其对血小板聚集的抑制作用

目的 设计并合成6-(4-取代苯基)-4,5-二氢-3(2H)-哒嗪酮类化合物,以期发现作用更强的血小板聚集抑制剂。方法以乙酰苯胺为原料,经酰化反应、傅-克反应、水解反应及水合肼环合反应、氯化反应、烷基化反应等一系列反应合成目标化合物,并参考Bom方法进行体外药理实验。结果共合成6-(4-取代苯基)-4,5-二氢-3(2H)-哒嗪酮类化合物11个,均属首次报道,并通过元素分析、^1HNMR、IR确证结构。初步的体外药理实验表明：大部分目标化合物都不同程度地抑制了ADP诱导的新西兰大白兔血小板的聚集。结论11个目标化合物中化合物(8)抑制血小板聚集作用的活性最强,超过对照化合物CCI-17810,化合物(1)、(2)、(4)等也有较强的活性。     

Synthesis and biological activity of the four stereoisomers of 6-[4-[3-[[2-hydroxy-3-[4-[2- (cyclopropylmethoxy)ethyl]phenoxy]propyl]amino]-propionamido] phenyl]-5-methyl-4,5-dihydro-3(2H)-pyridazinone, a combined vasodilator and beta-adrenoceptor antagonist

6-[4-[3-[[2-Hydroxy-3-[4-[2- (cyclopropylmethoxy)ethyl]phenoxy]propyl]amino]propionamido] phenyl]- 5-methyl-4,5-dihydro-3(2H)-pyridazinone (3) consists of a mixture of four stereoisomers, i.e., two racemates, as a consequence of the two asymmetric centers contained in the structure. An approximately equimolar mixture of these two racemates exhibits a novel combination of vasodilation and beta-adrenergic antagonist activity. This paper describes the synthesis of each of the four possible stereoisomers of 3 and provides clear evidence for the different pharmacological profile of each of the stereoisomers. The RA,SB isomer 3a has an overall profile slightly better than the complete mixture; the other three isomers all show reduced activity as vasodilators and/or beta-adrenergic antagonists.     

Syntheses of 1-Aryl-2-{4-[4-(3-oxobutyl)phenyl]piperazin-1-yl}ethanones

Syntheses of the biologically active N¹-[4-(3-oxobutyl)phenyl]-N⁴-phenacylpiperazines 1a-g from N-phenylpiperazine (2) are described.     

4-[4-(5-氧代-1,5-二氢-[1,2,4]三唑-4-基)苯基]哌嗪-1-羧酸叔丁酯的合成工艺改进

目的 改进三唑类抗真菌药物关键中间体4-[4-（5-氧代-1，5-二氢-[1，2，4]三唑-4-基）苯基]哌嗪-1-羧酸叔丁酯的合成工艺。方法 以1-（4-硝基苯基）哌嗪为起始原料，经Boc保护、硝基还原、酰化、肼解、环合制得目标化合物。结果与结论 新工艺反应条件温和，无需柱色谱纯化，总收率从39．10％提高至71．94％。     

Synthesis of new 4,5-3(2H)pyridazinone derivatives and their cardiotonic,hypotensive, and platelet aggregation inhibition activities

4,5-dihydro-3(2H)pyridazinones such as CI-914, CI-930 and pimobendan along with tetrahydropyridopyridazine (endralazine) and perhydropyridazinodiazepine (cilazopril) have been used as potent positive inotropes, antihypertensives as well as platelet aggregation inhibitors. Accordingly, the present work involves the synthesis of 24 target compounds; 4,5-dihydro-3(2H)pyridazinones in addition to seven reported intermediates. The chemical structures of the new compounds were assigned by microanalysis, IR, ¹H-NMR spectral analysis and some representatives by mass spectrometry. The positive inotropic effect of the final compounds and the intermediates 12a–12d as well as the reported intermediate compound 10 was determined in-vitro on isolated rabbit heart in comparison to digoxin. Data obtained revealed that twelve of the test compounds exhibited higher effective response than digoxin, nine compounds elicited comparable effects to digoxin and eight compounds were less active than digoxin. In addition, four compounds approved marked significant hypotensive effect better than that of the previously reported compound 10. Moreover, two compounds induced complete platelet aggregation inhibition. The last two compounds were also subjected to determination of their LD₅₀ and they showed no signs of toxicity up to the dose level 300 mg/kg (i.p.), while the reported oral LD₅₀ of digoxin is 17.78 mg/kg. Correlation of cardiotonic and hypotensive activities with structures of compounds was tried and pharmacophore models were computed to get useful insight onto the essential structural features required for inhibiting phosphodiesterase-III in the heart muscles and blood vessels.     

Synthesis of 2-(4-substitutedbenzyl-[1,4]diazepan-1-yl)-n-(1-methyl-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolin-7-yl)acetamides as inotropic agents

In an attempt to search for more potent positive inotropic agents, a series of N-(4,5-dihydro-1-methyl-[1,2,4]triazolo[4,3-a]quinolin-7-yl)-2-(substitutedbenzyl-[1,4]diazepan-1-yl)acetamides were synthesized and evaluated for positive inotropic activity by measuring left atrium stroke volume in isolated rabbit heart preparations. Some of these derivatives exhibited favorable activity compared with the standard drug, milrinone, among which 2-(4-(4-methylbenzyl)-[1,4]-diazepan-1-yl)-N-(4,5-dihydro-1-methyl-[1,2,4]triazolo[4,3-a]quinolin-7-yl)acetamide (6m) was the most potent, increasing stroke volume by 8.38±0.16% (milrinone 2.45± 0.06%) at 3 x 10(-5) m. The chronotropic effects of those compounds having inotropic effects were also evaluated in this work.